News

In the phase IIa trial evaluating Idenix’ lead drug candidate valopicitabine, patients are randomized to one of two treatment arms, valopicitabine (NM283) monotherapy, or valopicitabine (NM283) plus pegylated

CCR5 mAb (CCR5mAb004) is a fully human monoclonal antibody that specifically recognizes and binds the chemokine receptor CCR5. The CCR5 receptor is known to be a key facilitator

“Through our investment in antisense we have advanced the technology to a point where we and our partners now have extensive clinical and pre-clinical development pipelines that are

Zymed produces pathology products, cancer and cell biology reagents and biomarkers, and general immunochemical reagents for the life science research and clinical diagnostics markets. Its antibody collection is

The proposed label expansion for Aceon (perindopril erbumine,)an angiotensin converting enzyme (ACE) inhibitor with tissue activity approved in the US for the treatment of patients with essential hypertension,

SB-509 is an injectable formulation of plasmid DNA that encodes a zinc finger DNA-binding protein transcription factor (ZFP TF), designed to upregulate the vascular endothelial growth factor A

The collaborators published their initial findings in April 2004 in a New England Journal of Medicine article. While the previous study was based on samples from patients receiving

The phase III trial, named SHEPHERD, together with the already enrolling pivotal efficacy trial called TRIUMPH, comprise the phase III paroxysmal nocturnal hemoglobinuria (PNH) program which was agreed

Under the multi-year research collaboration, ComGenex will apply its proprietary Matrix technology, using in silico tools to expedite the design of targeted compound libraries. In addition, ComGenex will